DexComvsMerck & Company

DXCM and MRK stock compared: price, dividend, valuation and results, from SEC filings.

DXCM

DexCom, Inc.

$82.52

Value $31.8B

+0.53%
DXCM's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-0.75%
MRK's page

DexCom (DXCM) has a market value of $31.8B and Merck & Company (MRK) $341B. Over the last year, with dividends, DXCM moved +41.3% and MRK +58.8%. The P/E is 32.1 for DXCM and 138.9 for MRK. Dividend yield: DXCM none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    DXCM$31.8B

    MRK$341B

    MRK is 11 times DXCM

  • Revenue, 12 months

    DXCM$5.1B

    MRK$67.4B

    MRK is 13 times DXCM

  • Net income, 12 months

    DXCM$991M

    MRK$2.5B

    MRK is 2.5 times DXCM

  • Operating margin

    DXCM24.0%

    MRK–

  • ROIC

    DXCM19.5%

    MRK3.9%

    15.6 points apart

  • P/E

    DXCM32.1

    MRK138.9

    MRK is 4.3 times DXCM

  • Dividend yield

    DXCM0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    DXCM-49.4%

    MRK+98.6%

    148.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

DXCM-49.4%

MRK+98.6%

5010015020020222023202420252026
Returns by period
PeriodDXCMWith dividendsMRKWith dividends
1 year since November 14, 2025+41.3%Price +41.3%+58.8%Price +54.3%
3 years since November 17, 2023-21.8%-7.9% a yearPrice -21.8%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021-49.4%-12.7% a yearPrice -49.4%+98.6%+14.7% a yearPrice +70.5%
10 years since November 18, 2016+359.6%+16.5% a yearPrice +359.6%+229.5%+12.7% a yearPrice +142.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

DXCMDexComMRKMerck & Company

Valuation

DXCMMRK
Valuation
Price$82.52$137.78
Market value$31.8B$341B
Enterprise value (EV)$31.4B$385B
P/E32.1138.9
P/E, 5-year median54.814.8
P/B12.57.6
EV/EBIT25.680.8
Free cash flow yield3.5%4.3%

Results and growth

DXCMMRK
Results and growth
Revenue, 12 months$5.1B$67.4B
Net income, 12 months$991M$2.5B
Free cash flow, 12 months$1.1B$14.7B
Earnings per share, 12 months$2.54$0.98
Revenue growth, year on year15.6%1.3%
Revenue growth a year, past+19.3%over 5 years+9.4%over 5 years
EPS growth a year, past+44.4%over 5 years+21.2%over 5 years

Margins and returns on capital

DXCMMRK
Margins and returns on capital
Gross margin63.4%71.8%
Operating margin24.0%–
Net margin19.4%3.6%
ROIC19.5%3.9%
ROE36.5%5.2%

Balance sheet

DXCMMRK
Balance sheet
Cash$1.7B$9.7B
Total debt$1.4B$53.8B
Net debt / EBITDA-0.35.7
Interest cover128.8×2.4×

Dividends and buybacks

DXCMMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield1.6%1.5%
Shareholder yield1.6%4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: DXCM or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, DexCom or Merck & Company?

By market value, Merck & Company ($341B) is about 10.7 times DexCom ($31.8B), at today's prices.

How did DXCM and MRK stock do over the last 10 years?

Since November 18, 2016, DXCM's price moved +359.6% and MRK's +142.8%. With dividends: DXCM +359.6% (+16.5% a year), MRK +229.5% (+12.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, DXCM or MRK?

The dividend yield at today's price is none for DexCom and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of DXCM and MRK?

At today's price, the P/E is 32.1 for DXCM and 138.9 for MRK. The median of the last five years was 54.8 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, DexCom or Merck & Company?

Over the last twelve months, the net margin was 19.4% for DexCom and 3.6% for Merck & Company, and the operating margin 24.0% and –. Revenue was $5.1B and $67.4B.

Which is the better investment, DexCom or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.